Abstract:Multiple myeloma is a malignancy arising from postgerminal nature B cells. The estimated incidence of multiple myeloma accounts for 10% of hematological malignancies and 1% of all malignancies. Despite therapeutic advance, the disease is essentially incurable. Fatty acid synthase (FAS), the principle enzyme in the endogenous synthsis of fatty acid, is highly expressed in a wide variety of human malignancies and their presursor lesions, including carcinoma of the colon, prostate, ovary, endometrium and breast. One therapeutic target that has not previously been considered for multiple myeloma treatment is the pathway of the endogenous synthesis of fatty acid. For this purpose, we first evaluated a series of human multiple myeloma cases, bone marrow samples for FAS expression by immunohistochemistry, then established FAS mRNA and protein expression in multiple myeloma cell lines and human multiple myeloma plasma cells by RT-PCR and immunoblot analysis. Our results showed that 19 of the 27(70.37%) MM cases were scored as FAS positive by immunohistochemistry, whereas 8 of the 27 (29.64%) were scored negative. FAS mRNA was highly expressed in U266, RPMI8226 cells and 22 of the 27 MM patients, but wasn't detected in healthy donor PBMNCs by RT-PCR. Immunoblot analysis found that FAS protein was detected in 16 of the 27 patients(59.25%) and two above myeloma cell lines but not detected in healthy donor PBMNCs. Encouraged by these findings that human multiple myeloma bone marrow samples and cell lines overexpress FAS, we treated human multiple myeloma cell lines (U266, RPMI8226) in vitro with cerulenin, a native inhibitor of FAS. Cells proliferation was measured by methyl thiazolyl tetrazolium(MTT) analysis and apoptosis was evaluated by flow cytometry. Treat with 5ug/ml—640ug/ml of cerelenin for 24h, the proliferation of U266 cells was obviously inhibited with dosage related effect. The inhibition rate of human skin fibroblast cells are all lower than 30%. When U266 cells are treated for 12h with 20ug/ml of cerulenin, the early stage apoptosis rate revealed by Annxin V/PI using FCM are 56,9%. Our findings suggest that FAS may be an effective target for pharmacological therapy in human multiple myeloma.

Lactoferrin-Derived Peptide Chimera Induces Caspase-independent Cell Death in Multiple Myeloma

Increased Fatty Acid Synthase is a Therapeutic Target in Multiple Myeloma.

Increased Fatty Acid Synthase As a Potential Therapeutic Target in Multiple Myeloma

Study on Proliferation Inhibiting and Apoptosis Inducing Effects of Cerulenin on Multiple Myeloma Cells

Polyphyllin I Induces Cell Cycle Arrest and Apoptosis in Human Myeloma Cells Via Modulating Β‐catenin Signaling Pathway

Halting Multiple Myeloma with MALT1 Inhibition: Suppressing BCMA-Induced NF-κB and Inducing Immunogenic Cell Death

Proteasome Inhibitor Lactacystin Augments Natural Killer Cell Cytotoxicity of Myeloma Via Downregulation of HLA Class I

A phenylphthalimide derivative, TC11, induces apoptosis by degrading MCL1 in multiple myeloma cells

Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma

Inhibition of Acyl-CoA Synthetase Long Chain Isozymes Decreases Multiple Myeloma Cell Proliferation and Causes Mitochondrial Dysfunction

Fibroblast Growth Factor Receptor 3 Inhibition by Short Hairpin RNAs Leads to Apoptosis in Multiple Myeloma

IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB– and caspase-8–dependent mechanisms

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics

Function of NLRP3 inflammasome activation in multiple myeloma

Short Communication: Expression of Apoptosis Regulating Factors on T Lymphocytes in Multiple Myeloma Patients

Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells

Cold Atmospheric Plasma As a Potential Tool for Multiple Myeloma Treatment

A Inhibits Multiple Myeloma Cell Growth Through Induction 53-Mediated Caspase-Dependent Apoptosis and Ergistically Enhances Nutlin-Induced

Disruption of Lipid Raft Microdomains, Regulation of CD38, TP53, and MYC Signaling, and Induction of Apoptosis by Lomitapide in Multiple Myeloma Cells

Cell Death Triggers Induce MLKL Cleavage in Multiple Myeloma Cells, Which may Promote Cell Death

Inhibition of breast cancer xenografts in a mouse model and the induction of apoptosis in multiple breast cancer cell lines by lactoferricin B peptide